title: Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?
abstract: The recently published Heart Outcomes Prevention Evaluation trial (HOPE-3) demonstrated no benefit of lowering blood pressure with candesartan and hydrochlorothiazide in persons at intermediate cardiovascular risk and with adequate blood pressure control as determined by the enrolling physician. The results of Systolic Blood Pressure Intervention Trial (SPRINT) and HOPE-3 highlight the importance of considering differences in study design and patient population when interpreting the results of clinical trials.
authors: Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: christina.wyatt@mssm.edu.
authors: Christina M
authors: CM
authors: Wyatt
authors: Department of Medicine, Division of Nephrology, Stanford School of Medicine, Stanford, California, USA.
authors: Glenn M
authors: GM
authors: Chertow
mesh_terms: D000959:Antihypertensive Agents; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases; D006801:Humans; D006852:Hydrochlorothiazide; D006973:Hypertension; D012307:Risk Factors
chemical_list: D000959:Antihypertensive Agents; D006852:Hydrochlorothiazide